Sugi Predict

Sugi Predict / Compounds / SCHEMBL1050653

SCHEMBL1050653

SCHEMBL1050653

NCc1ccc2[nH]cnc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ APEX1 P27695 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ BLM P54132 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ PRKCI P41743 1/20 0.44
▸ RAD52 P43351 1/20 0.43
▸ GAA P10253 1/20 0.42
▸ PKM P14618 1/20 0.42
▸ QPCT Q16769 1/20 0.39
▸ DPP4 P27487 2/20 0.38
▸ DPP8 Q6V1X1 1/20 0.38
▸ LOXL2 Q9Y4K0 2/20 0.37
▸ LOX P28300 1/20 0.37
▸ LOXL3 P58215 1/20 0.37
▸ MMP12 P39900 1/20 0.37
▸ ASIC3 Q9UHC3 1/20 0.37
▸ ROCK1 Q13464 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL32671448 0.98 MAPT (0.46) MAPTKDM4EALDH1A1APEX1RECQL
Hydrochloric Acid SCHEMBL7220537 0.98 MAPT (0.46) MAPTKDM4EALDH1A1APEX1RECQL
Hydrochloric Acid SCHEMBL3632899 0.98 MAPT (0.46) MAPTKDM4EALDH1A1APEX1RECQL
SCHEMBL14308045 0.86 HRH3 (0.47) MAPTKDM4EALDH1A1APEX1RECQL
SCHEMBL17195989 0.85 PRKCI (0.46) MAPTKDM4EALDH1A1APEX1RECQL
SCHEMBL7026387 0.85 PRKCI (0.58) MAPTKDM4EALDH1A1APEX1RECQL
Hydrochloric Acid SCHEMBL30093282 0.84 MAPT (0.47) MAPTKDM4EALDH1A1APEX1RECQL
Hydrochloric Acid SCHEMBL30093290 0.84 MAPT (0.47) MAPTKDM4EALDH1A1APEX1RECQL
Hydrochloric Acid SCHEMBL7220540 0.83 KDM4E (0.59) MAPTKDM4EALDH1A1APEX1RECQL
SCHEMBL3796386 0.82 MAPT (0.42) MAPTKDM4EALDH1A1APEX1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018048930-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. (US) 2018-03-15 — — WO claimed
US-20160250208-A1 TREATING ORGAN-SPECIFIC T CELL MEDIATED AUTOIMMUNE DISEASES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-09-01 — — US claimed
WO-2015054612-A1 TREATING ORGAN-SPECIFIC T CELL MEDIATED AUTOIMMUNE DISEASES UNIVERSITY OF MASSACHUSETTS (US) 2015-04-16 — — WO claimed
US-20250388606-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS MIRATI THERAPEUTICS INC (US) 2025-12-25 — — US disclosed
US-12398154-B2 Azaquinazoline pan-KRas inhibitors Mirati Therapeutics, Inc. (US) 2025-08-26 — — US disclosed
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-04-24 — — US disclosed
WO-2025064718-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-03-27 — — WO disclosed
CN-110832070-B Expansion of liquid tumor-derived tumor infiltrating lymphocytes and therapeutic uses thereof 艾欧凡斯生物治疗公司 2024-12-27 — — CN disclosed
CN-113748202-B Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof 艾欧凡斯生物治疗公司 2024-07-16 — — CN disclosed
EP-4262807-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-10-25 — — EP disclosed
US-20230072276-A1 Azaquinazoline pan-KRas inhibitors Mirati Therapeutics, Inc. 2023-03-09 — — US disclosed
EP-1124822-A4 THROMBIN INHIBITORS MERCK & CO INC (US) 2002-04-03 — — EP disclosed
US-20020032238-A1 Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-14 — — US disclosed
WO-2002004403-A1 BIPHENYLCARBOXYLIC ACID AMIDES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-01-17 — — WO disclosed
EP-1124822-A1 THROMBIN INHIBITORS Merck & Co., Inc. (US) 2001-08-22 — — EP disclosed
WO-2000032574-A1 NOVEL 2-PYRIDONE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USE SANOFI-SYNTHELABO (FR) 2000-06-08 — — WO disclosed
WO-2000026211-A1 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2000-05-11 — — WO disclosed
EP-0680469-B1 AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME BOEHRINGER INGELHEIM PHARMA (DE) 2000-04-26 — — EP disclosed
US-5807875-A OBESITY THERAPY DR. KARL THOMAE GMBH (DE) 1998-09-15 — — US disclosed
US-5616620-A HYPOTENSIVE AGENTS KARL THOMAE GMBH (DE) 1997-04-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032238-A1 Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments MTTP, CETP, FABP1 MAPT 4022/4885KDM4E 1707/4885ALDH1A1 190/4885
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS MYC, KRAS, NRAS MAPT 2071/4885KDM4E 2083/4885ALDH1A1 2630/4885
US-20230072276-A1 Azaquinazoline pan-KRas inhibitors KRAS, NRAS, HRAS MAPT 4490/4885KDM4E 1646/4885ALDH1A1 4127/4885
US-12398154-B2 Azaquinazoline pan-KRas inhibitors KRAS, NRAS, HRAS MAPT 4490/4885KDM4E 1646/4885ALDH1A1 4127/4885
US-20250388606-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS KRAS, NRAS, HRAS MAPT 4874/4885KDM4E 2645/4885ALDH1A1 3580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.